NASDAQ:CRVO CervoMed (CRVO) Stock Price, News & Analysis $9.33 +0.50 (+5.66%) Closing price 04:00 PM EasternExtended Trading$9.58 +0.25 (+2.72%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CervoMed Stock (NASDAQ:CRVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CervoMed alerts:Sign Up Key Stats Today's Range$8.76▼$9.9750-Day Range$5.56▼$8.9852-Week Range$1.80▼$20.63Volume363,189 shsAverage Volume808,955 shsMarket Capitalization$81.17 millionP/E RatioN/ADividend YieldN/APrice Target$21.50Consensus RatingModerate Buy Company Overview CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts. Read More CervoMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreCRVO MarketRank™: CervoMed scored higher than 54% of companies evaluated by MarketBeat, and ranked 480th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingCervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageCervoMed has only been the subject of 3 research reports in the past 90 days.Read more about CervoMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CervoMed are expected to grow in the coming year, from ($1.88) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CervoMed is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CervoMed is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCervoMed has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CervoMed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.95% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently increased by 18.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCervoMed does not currently pay a dividend.Dividend GrowthCervoMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.95% of the float of CervoMed has been sold short.Short Interest Ratio / Days to CoverCervoMed has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CervoMed has recently increased by 18.68%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.54 News SentimentCervoMed has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for CervoMed this week, compared to 2 articles on an average week.Search Interest7 people have searched for CRVO on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CervoMed insiders have not sold or bought any company stock.Percentage Held by Insiders35.40% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.15% of the stock of CervoMed is held by institutions.Read more about CervoMed's insider trading history. Receive CRVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVO Stock News HeadlinesCanaccord Genuity Group Raises CervoMed (NASDAQ:CRVO) Price Target to $27.00July 31, 2025 | americanbankingnews.comCervoMed stock soars after positive dementia drug trial dataJuly 29, 2025 | za.investing.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 4 at 2:00 AM | Brownstone Research (Ad)CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The StockJuly 29, 2025 | msn.comCervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of NeurodegenerationJuly 28, 2025 | globenewswire.comCervoMed's (CRVO) "Buy" Rating Reiterated at D. Boral CapitalJuly 28, 2025 | americanbankingnews.comCervoMed Q2 2025 Earnings PreviewJuly 25, 2025 | msn.comCervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3July 9, 2025 | finance.yahoo.comSee More Headlines CRVO Stock Analysis - Frequently Asked Questions How have CRVO shares performed this year? CervoMed's stock was trading at $2.34 at the start of the year. Since then, CRVO shares have increased by 298.7% and is now trading at $9.33. How were CervoMed's earnings last quarter? CervoMed Inc. (NASDAQ:CRVO) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.60) by $0.04. The company earned $1.92 million during the quarter, compared to analysts' expectations of $1.70 million. CervoMed had a negative net margin of 200.57% and a negative trailing twelve-month return on equity of 44.07%. How do I buy shares of CervoMed? Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CervoMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2025Today8/04/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVO Previous SymbolNASDAQ:CRVO CIK1053691 Webdiffusionpharma.com Phone14342200718Fax434-220-0722Employees4Year FoundedN/APrice Target and Rating Average Price Target for CervoMed$21.50 High Price Target$42.00 Low Price Target$10.00 Potential Upside/Downside+130.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.29 million Net Margins-200.57% Pretax Margin-200.57% Return on Equity-44.07% Return on Assets-40.65% Debt Debt-to-Equity RatioN/A Current Ratio9.78 Quick Ratio9.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.50 per share Price / Book2.07Miscellaneous Outstanding Shares8,703,000Free Float5,622,000Market Cap$81.20 million OptionableNot Optionable Beta-0.79 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CRVO) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CervoMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CervoMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.